INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 174 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2014. The put-call ratio across all filers is 0.46 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $8,056,000 | -30.7% | 74,150 | +5.0% | 0.89% | -21.8% |
| Q3 2016 | $11,628,000 | +49.1% | 70,651 | +29.3% | 1.14% | +41.7% |
| Q2 2016 | $7,798,000 | -75.3% | 54,651 | -77.7% | 0.80% | -47.2% |
| Q1 2016 | $31,533,000 | -4.1% | 245,447 | +11.5% | 1.52% | +8.9% |
| Q4 2015 | $32,864,000 | -9.8% | 220,047 | +0.2% | 1.40% | -16.1% |
| Q3 2015 | $36,431,000 | -15.0% | 219,647 | +23.6% | 1.67% | -6.7% |
| Q2 2015 | $42,880,000 | -7.8% | 177,647 | +7.7% | 1.79% | +1.3% |
| Q1 2015 | $46,518,000 | +64.0% | 164,947 | -9.3% | 1.77% | +38.8% |
| Q4 2014 | $28,368,000 | +53.9% | 181,847 | +133.5% | 1.27% | +63.9% |
| Q3 2014 | $18,436,000 | +5.3% | 77,893 | +5.3% | 0.78% | +4.6% |
| Q2 2014 | $17,509,000 | -28.7% | 73,993 | -0.7% | 0.74% | -26.6% |
| Q1 2014 | $24,567,000 | – | 74,493 | – | 1.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |